- SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSISHu, Yue; Li, Haijun; Zhang, Hong; Chen, Jinjun; Xu, Zhongyuan; You, Hong; Dong, Ruihua; Zhu, Xiaoxue; Chen, Hong; Peng, Yun; Li, Jing; Wu, Dandan; Li, Xiaojiao; Zhang, Lei; Cao, Di; Jin, He; Qiu, Dongdong; Yang, Aruhan; Liu, Jingrui; Jia, Haiyan; Lou, Jinfeng; Niu, Junqi; Ding, Yanhua
- Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib studyHu, Yue; Li, Hai Jun; Zhang, Hong; Chen, Jinjun; Xu, Zhongyuan; You, Hong; Dong, Ruihua; Zhu, Xiaoxue; Chen, Hong; Peng, Yun; Li, Jing; Li, Xiaojiao; Zhang, Lei; Cao, Di; Jin, He; Qiu, Dongdong; Yang, Aruhan; Liu, Jingrui; Jia, Haiyan; Lou, Jinfeng; Niu, Junqi; Ding, Yanhua被引 1
- Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASHMin Yong Yoon; Jun Mo Sung; Chang Seok Song; Won Young Lee; Eun Jung Rhee; Jun Ho Shin; Chang Hak Yoo; Seoung Wan Chae; Ja Yeon Kim; Wook Jin; Yong Kyun ChoClinical and Molecular Hepatology, 2012, 18(3): 279.
会议论文
NOVEL, FIRST-IN-CLASS, FATTY ACID SYNTHASE (FASN) INHIBITOR TVB-2640 DEMONSTRATES ROBUST CLINICAL EFFICACY AND SAFETY IN A GLOBAL PHASE 2 RANDOMIZED PLACEBO-CONTROLLED NASH TRIAL (FASCINATE-1) CONDUCTED IN THE US AND CHINA
9阅读
